Cargando…
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
BACKGROUND: Promacta (eltrombopag; EPAG) and Nplate (romiplostim; ROMI) have not been compared in head-to-head trials for treatment of chronic immune thrombocytopenia (cITP); however, indirect treatment comparisons have indicated similar efficacy and safety outcomes, and the drugs are generally acce...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394751/ https://www.ncbi.nlm.nih.gov/pubmed/34278835 http://dx.doi.org/10.18553/jmcp.2021.21080 |